Recombinant human erythropoietin (rhEPO) in anemia associated with multiple myeloma and non-Hodgkin’s lymphoma
Anemia is observed in most patients with multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) and may already be manifested at the time of diagnosis. In patients with MM, hemoglobin values <10.0g/dL were found in 49% and severe anemia (hemoglobin <7.5 g/dL) in 19% of the patients already at the time of diagnosis (MRC working party 1980). Patients with NHL have been reported to have an anemia rate of approximately 40% (Coiffier 1999). Anemia usually (but not always, especially in MM) normalizes in patients who achieve complete remission after chemotherapy. However, it persists in patients who are unresponsive to treatment, and recurs in those with relapsing disease. Anemia is a general finding in later phases of the disease, when toxicity of long-term treatment, impairment of renal function, and heavy tumor load contribute to its induction and aggravation.
KeywordsMultiple Myeloma Chronic Lymphocytic Leukemia Recombinant Human Erythropoietin rhEPO Treatment Cumulative Response Rate
Unable to display preview. Download preview PDF.
- Bessho M, Hirashima K, Tsuchiya J (1994) Improvement of anemia in patients with multiple myeloma by recombinant erythropoietin: A multicenter study. Exp Hematol 22: 705 (abstract)Google Scholar
- Cazzola M, Messinger D, Battistel V, Bron D, Cimino R, Enller-Ziegler L, Essers U, Greil R, Grossi A, Jager G et al (1995) Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of response. Blood 86: 4446–4453PubMedGoogle Scholar
- Dammacco F, Castoldi G, Rödjer S et al (1997) A placebo-controlled study on the effect of epoetin alpha in patients with multiple myeloma. Blood 90 (Suppl 1): 358aGoogle Scholar
- Henry D, Glaspy J (1997) Predicting response to epoetin alfa in anemic cancer patients receiving chemorx. Proc Am Soc Clin Oncol 16: 49a (abstract)Google Scholar
- Musto P, Falcone A, D’Arena G, Scalzulli PR, Matera R, Minervini MM, Lombardi GF, Modoni S, Longo A, Carotenuto M (1997) Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol 58: 314–319PubMedCrossRefGoogle Scholar
- Rose E, Rai K, Revicki D, Brown R, Reblando J (1994) Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 84 (Suppl 1): 526aGoogle Scholar
- Stockman JA III (1996) Anemia of prematurity. Current concepts in the issue of when to transfuse. Pediatr Clin North Am 33: 111–128Google Scholar
- Thomas ML (1998) Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Medical Oncology 15 (Suppl 3): 13–18Google Scholar
- Österborg A, Boogaerts M, Cimino R, Essers U, Holowiecki J, Juliusson G, Jager G, Najman A, Peest D (1996) Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma-A randomized multicenter study. Blood 87: 2675–2682PubMedGoogle Scholar
- Österborg A (1998) Recombinant human erythropoietin s(rHuEPO) therapy in patients with cancer-related anaemia: What have we learned? Med Oncol 15 (Suppl 1): 47–49Google Scholar
- Österborg A, Brandberg Y, Molostova V, Iosova V, Abdulkadyrov K, Hedenus M, Messinger D (2002) Randomized, double-blind, placebo-controlled trial of the effect of epoetin beta on quality of life of patients with hematological malignancies. J Clin Oncol 20: in pressGoogle Scholar